Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDI-Ion Mobility Separation-Mass Spectrometry Imaging
Djidja, M-C. Francese, S. Claude, E. Sutton, Chris W. Cooper, Patricia A. Patterson, Laurence H. Carolan, V.A. Clench, M.R.
Djidja, M-C.
Francese, S.
Claude, E.
Sutton, Chris W.
Cooper, Patricia A.
Patterson, Laurence H.
Carolan, V.A.
Clench, M.R.
Publication Date
01/04/2013
End of Embargo
Supervisor
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Hypoxia is a common feature observed in solid tumours. It is a target of interest in oncology as it has been found to be closely associated with tumour progression, metastasis and aggressiveness and confers resistance to a variety of chemotherapeutic agents as well as radiotherapy. AQ4N, also known as banoxatrone or 1,4-bis-[2-(dimethylamino-Noxide) ethyl]amino-5,8-dihydroxyanthracene-9,10-dione is a very promising bioreductive prodrug. This paper, describes an application of MALDI-MSI combined with ion mobility separation and an "on-tissue" bottom up proteomic strategy to obtain proteomic data from AQ4N dosed tumour xenograft tissue sections. These data are then correlated with the drug distribution determined also using MALDI-ion mobility separation-mass spectrometry imaging (MALDI-IMS-MSI). PCA-DA and OPLS-DA have been used to compare treated and untreated xenografts and of note is the marked increase in expression of Histone H3.
Version
No full-text in the repository
Citation
Djidja M, Francese S, Claude E et al (2013) Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDIIon Mobility Separation-Mass Spectrometry Imaging. Current Analytical Chemistry. 9(2): 212-225.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article